Françoise Isnard

2.9k total citations
29 papers, 1.0k citations indexed

About

Françoise Isnard is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Françoise Isnard has authored 29 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 9 papers in Genetics and 8 papers in Molecular Biology. Recurrent topics in Françoise Isnard's work include Acute Myeloid Leukemia Research (19 papers), Antifungal resistance and susceptibility (6 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers). Françoise Isnard is often cited by papers focused on Acute Myeloid Leukemia Research (19 papers), Antifungal resistance and susceptibility (6 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers). Françoise Isnard collaborates with scholars based in France, Belgium and United States. Françoise Isnard's co-authors include Anne Vekhoff, Felipe Suárez, Sébastien Maury, Lionel Adès, F. Foulet, Catherine Cordonnier, Frédérique Kuhnowski, Stéphane Bretagne, Nathalie Dhédin and Cécile Pautas and has published in prestigious journals such as Blood, PLoS ONE and Diabetes Care.

In The Last Decade

Françoise Isnard

28 papers receiving 999 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Françoise Isnard France 14 450 449 260 237 218 29 1.0k
Constantijn J.M. Halkes Netherlands 20 353 0.8× 133 0.3× 418 1.6× 210 0.9× 219 1.0× 60 1.2k
Timoleon‐Achilleas Vyzantiadis Greece 17 283 0.6× 228 0.5× 165 0.6× 97 0.4× 85 0.4× 73 803
Francesco Equitani Italy 14 332 0.7× 194 0.4× 284 1.1× 146 0.6× 154 0.7× 34 909
F B Taylor United States 14 336 0.7× 50 0.1× 464 1.8× 54 0.2× 145 0.7× 18 1.1k
R E Pounder United Kingdom 12 372 0.8× 67 0.1× 80 0.3× 65 0.3× 110 0.5× 18 1.2k
Subhash Varma India 15 70 0.2× 89 0.2× 195 0.8× 84 0.4× 112 0.5× 61 651
Rafik Karmali Belgium 16 231 0.5× 257 0.6× 39 0.1× 159 0.7× 146 0.7× 53 1.1k
Morio Sawamura Japan 17 73 0.2× 66 0.1× 453 1.7× 235 1.0× 295 1.4× 86 1.0k
Guillermo Ortí Spain 12 128 0.3× 85 0.2× 364 1.4× 226 1.0× 113 0.5× 32 849
Sanit Makonkawkeyoon Thailand 9 250 0.6× 324 0.7× 251 1.0× 99 0.4× 169 0.8× 20 862

Countries citing papers authored by Françoise Isnard

Since Specialization
Citations

This map shows the geographic impact of Françoise Isnard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Françoise Isnard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Françoise Isnard more than expected).

Fields of papers citing papers by Françoise Isnard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Françoise Isnard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Françoise Isnard. The network helps show where Françoise Isnard may publish in the future.

Co-authorship network of co-authors of Françoise Isnard

This figure shows the co-authorship network connecting the top 25 collaborators of Françoise Isnard. A scholar is included among the top collaborators of Françoise Isnard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Françoise Isnard. Françoise Isnard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Labopin, Myriam, Anne‐Claire Mamez, Simona Lapusan, et al.. (2019). Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia. Bone Marrow Transplantation. 55(2). 452–460. 11 indexed citations
2.
3.
Picod, Adrien, Agnès Bonnin, Giorgia Battipaglia, et al.. (2018). Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study. Biology of Blood and Marrow Transplantation. 24(7). 1471–1475. 19 indexed citations
4.
5.
Hirsch, Pierre, Ruoping Tang, Nasséra Abermil, et al.. (2017). Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia. Haematologica. 102(7). 1227–1237. 38 indexed citations
6.
Kempf, Emmanuelle, Pierre Hirsch, Myriam Labopin, et al.. (2014). Prognosis of body mass index and chemotherapy dose capping in acute myeloid leukaemia. Leukemia Research. 38(12). 1425–1429. 11 indexed citations
7.
Hirsch, Pierre, Christophe Marzac, Ruoping Tang, et al.. (2014). Acute myeloid leukemia in patients older than 75: prognostic impact ofFLT3-ITDandNPM1mutations. Leukemia & lymphoma. 56(1). 147–150. 7 indexed citations
8.
Hirsch, Pierre, Myriam Labopin, Christine Pérot, et al.. (2014). Interest of cytogenetic and FISH evaluation for prognosis evaluation in 198 patients with acute myeloid leukemia in first complete remission in a single institution. Leukemia Research. 38(8). 907–912. 6 indexed citations
9.
Paubelle, Étienne, Florence Zylbersztejn, Felipe Suárez, et al.. (2013). Deferasirox and Vitamin D Improves Overall Survival in Elderly Patients with Acute Myeloid Leukemia after Demethylating Agents Failure. PLoS ONE. 8(6). e65998–e65998. 29 indexed citations
10.
Gorin, Norbert Claude, Françoise Isnard, Laurent Garderet, et al.. (2013). Administration of alemtuzumab and G‐CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study. European Journal Of Haematology. 91(4). 315–321. 20 indexed citations
11.
12.
Cordonnier, Catherine, Cécile Pautas, Sébastien Maury, et al.. (2009). Empirical versus Preemptive Antifungal Therapy for High‐Risk, Febrile, Neutropenic Patients: A Randomized, Controlled Trial. Clinical Infectious Diseases. 48(8). 1042–1051. 280 indexed citations
13.
Fabre, Claire, Laurence Legros, Sophie Park, et al.. (2006). Treatment of High Risk MDS and AML Post-MDS with Azacytidine (AZA): Preliminary Results of the French ATU Program.. Blood. 108(11). 2664–2664. 4 indexed citations
14.
Yeshurun, Moshe, et al.. (2001). Acute Liver Failure as Initial Manifestation of Low-Grade Non-Hodgkin's Lymphoma Transformation into Large-Cell Lymphoma. Leukemia & lymphoma. 42(3). 555–559. 7 indexed citations
15.
Gorin, Norbert Claude, Myriam Labopin, Jean-Philippe Laporte, et al.. (1999). Importance of marrow dose on posttransplant outcome in acute leukemia. Experimental Hematology. 27(12). 1822–1830. 37 indexed citations
16.
Lemoine, François M., Marie‐Laure Bonnet, Claude Baillou, et al.. (1997). Comparison of the Effects of AcSDKP, Thymosin β4, Macrophage Inflammatory Protein 1α and Transforming Growth Factor β on Human Leukemic Cells. Leukemia & lymphoma. 27(5-6). 487–494. 7 indexed citations
17.
Isnard, Françoise, et al.. (1997). Plasma Itraconazole Concentrations in Patients With Neutropenia. Therapeutic Drug Monitoring. 19(5). 525–529. 15 indexed citations
18.
Fontbonne, Annick, Marie‐Aline Charles, I. Juhan‐Vague, et al.. (1996). The Effect of Metformin on the Metabolic Abnormalities Associated With Upper-Body Fat Distribution. BIGPRO Study Group. Diabetes Care. 19(9). 920–926. 202 indexed citations
19.
Smadja, Nicole, et al.. (1995). Cytogenetic study in multiple myeloma at diagnosis: comparison of two techniques. British Journal of Haematology. 90(3). 619–624. 36 indexed citations
20.
Isnard, Françoise, Myriam Labopin, J. P. Laporte, et al.. (1994). Efficacy of Recombinant Human Erythropoietin in the Treatment of Refractory Anemias Without Excess of Blasts in Myelodysplastic Syndromes. Leukemia & lymphoma. 12(3-4). 307–314. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Constantijn J.M. Halkes Breakdown of academic impact, for papers by Timoleon‐Achilleas Vyzantiadis Breakdown of academic impact, for papers by Francesco Equitani Breakdown of academic impact, for papers by F B Taylor Breakdown of academic impact, for papers by R E Pounder Breakdown of academic impact, for papers by Subhash Varma Breakdown of academic impact, for papers by Rafik Karmali Breakdown of academic impact, for papers by Morio Sawamura Breakdown of academic impact, for papers by Guillermo Ortí Breakdown of academic impact, for papers by Sanit Makonkawkeyoon
Rankless by CCL
2026